LONDON- Drone Guarder, Inc. (OTCQB:DRNG): The Drone Guarder software and app development team have completed Version 2.0 of the DG Operating System, which provides seamless functionality with its apps, scheduled soon to be launched on Apple and Google app stores.
The 2.0 Operating System is the master program that manages the DG drone, which is autonomously App controlled. Our software is Linux based providing strengthened security features for our proprietary image and scanning recognition AI technology imbedded in the processor of the drone.
The completed development phase delivers full synergistic functionality between the drone and the app that includes: the self-alerting live video feed from the drone’s camera, day and night vision, dynamic text alert, enhanced stabilization and call home to base functions.
Adam Taylor (CEO of DG Inc) says, “We have reached another milestone in the development of the DG drone with our new version 2.0 operating system and app integration. These recently completed advancements of our latest software allow us to realize a November 2017 launch date of the final product release.”
About Drone Guarder, Inc.
DroneGuarder is an early stage security and surveillance company focusing on commercializing a drone enhanced home security system as a turnkey solution. The solution is app-based and includes a drone, infrared camera, and Android mobile app component: Once an alarm has been triggered, the DroneGuarder™ will immediately take off from a wireless charging pad.
Please visit http://www.droneguarder.com to learn about the company, management and products.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.